Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Pfizer Inc (PFE) Price & Performance

Halozyme Therapeutics Inc. Common StockTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Halozyme Therapeutics Inc. Common Stock vs Pfizer Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.45 (market cap $12.58B), while Pfizer Inc trades at $28.16 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 12.6× Halozyme Therapeutics Inc. Common Stock's market cap, and Pfizer Inc pays a 6.18% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Pfizer Inc for 158 Days on average.

HALOPFE
Market Cap
$12.58B$158.56B
Volume
2,179,27844,138,282
Sector
HealthHealth
52-Week High
$115.22$29.02
52-Week Low
$61.63$23.67
Typical Hold Time
0 Days158 Days
Enterprise Value
$14.49B$210.06B
Dividend Yield
—6.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Halozyme Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Pfizer Inc

Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.

The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HALO
100% Buy0% Sell
Avg holding period · 0 Days
PFE
70% Buy30% Sell
Avg holding period · 158 Days

Top news

Latest headlines on both assets

About Halozyme Therapeutics Inc. Common Stock

Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.

Read more on HALO →

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE →